HHS axes $700M Moderna bird flu vaccine contract — is this a pivot to more dangerous, self-replicating mRNA jabs?

In a stunning reversal, the U.S. government has abruptly terminated a $700 million contract with Moderna to develop an mRNA-based bird flu vaccine — raising urgent questions about whether this signals an end to pandemic fearmongering or merely a shift toward even riskier genetic injection technologies. While the cancellation offers a temporary reprieve from Moderna’s predatory vaccine schemes, skeptics warn that the vaccine industry may still be pushing forward with experimental “self-amplifying mRNA” (sa-mRNA) shots, a technology that forces the body to mass-produce viral proteins indefinitely.

Key points:

• The U.S. government has canceled Moderna’s $700 million bird flu vaccine contract, halting late-stage development of its H5N1 mRNA injection.
• Despite the cancellation, federal agencies are still funding next-generation “universal flu vaccines,” including self-replicating sa-mRNA platforms.
• Moderna’s CEO insists the company will pursue “alternative paths” for its bird flu jab, despite mounting evidence of mRNA vaccine injuries.
• The Biden autopen regime previously awarded Moderna $176 million for avian influenza vaccine development, raising concerns about ongoing pandemic profiteering.
• Health Freedom warriors warn that government-funded gain-of-function research on bird flu viruses is creating the very pandemics used to justify mass vaccination campaigns.

Moderna’s failed COVID empire and the push for bird flu jabs

Moderna’s financial survival has long depended on taxpayer-funded vaccine contracts, particularly after its COVID-19 shots — linked to heart damage, immune disorders and excess deaths — failed to secure long-term market demand. With plummeting stock prices and dwindling public trust, the company has aggressively lobbied governments to bankroll new pandemic threats, including avian influenza.

The now-canceled H5N1 contract was part of a broader push by the Biomedical Advanced Research and Development Authority (BARDA), an HHS agency notorious for funneling billions into Big Pharma’s experimental projects. Moderna had already received $176 million in 2023 to fast-track its mRNA bird flu shot, despite zero long-term safety data.

“These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats,” Moderna CEO Stéphane Bancel claimed in a press release — a statement that ignores the thousands of injuries reported from COVID-19 mRNA shots.

The rise of self-replicating mRNA: A more dangerous alternative?

While the cancellation appears to be a setback for Moderna, the government has not abandoned its pandemic preparedness agenda. Instead, federal agencies are quietly shifting toward even more experimental platforms, including self-amplifying mRNA (sa-mRNA) vaccines. Unlike traditional mRNA shots, which degrade quickly, sa-mRNA injections hijack the body’s cells to continuously produce viral proteins — a process with unknown long-term consequences.

In November 2023, FDA approved its sa-mRNA bird flu vaccine, ARCT-2304, signaling a dangerous new frontier in genetic experimentation. Meanwhile, the U.S. Government Accountability Office (GAO) confirmed plans for a “universal flu vaccine” trial in 2026, raising fears that synthetic, multi-strain injections could trigger catastrophic immune responses.

Gain-of-function: Manufacturing pandemics to sell the “cure”

The abrupt cancellation of Moderna’s contract does little to address the root of the problem: government-funded gain-of-function research that artificially engineers pandemic threats. Since early 2024, the USDA has been conducting high-risk experiments on H5N1 viruses — potentially enhancing their transmissibility — while simultaneously developing mRNA “solutions” for the very pathogens they helped create.

This corrupt cycle mirrors the COVID, where taxpayer-funded research at the Wuhan Institute of Virology preceded a global pandemic and unprecedented vaccine windfalls for companies like Moderna.

Will Moderna face accountability?

Despite the contract termination, Moderna shows no signs of retreating. The company recently opened a 290,000-square-foot U.K. facility capable of churning out 250 million vaccines annually, suggesting it still expects lucrative government contracts.

For those who have witnessed the devastation of COVID-19 mandates, the cancellation is a small victory—but the war is far from over. Until gain-of-function research is banned and vaccine manufacturers are held legally accountable for injuries, the medical police state will continue exploiting public health crises for profit.

Sources include:

Modernity.news

Investors.modernatx.com

JonFleetwood.substack.com